




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification⁵ : C07C 235/36, A61K 31/165 C07C 311/39, A61K 31/18 C07C 321/30, 255/60, 327/48 C07D 213/75</p>	A1	<p>(11) International Publication Number: WO 92/12961</p> <p>(43) International Publication Date: 6 August 1992 (06.08.92)</p>
<p>(21) International Application Number: PCT/GB92/00153</p> <p>(22) International Filing Date: 28 January 1992 (28.01.92)</p> <p>(30) Priority data: 9101777.2 28 January 1991 (28.01.91) GB 9117727.9 16 August 1991 (16.08.91) GB</p> <p>(71) Applicant (for all designated States except US): RHONE POULENC RORER LIMITED [GB/GB]; Rainham Road South, Dagenham, Essex RM10 7XS (GB).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only) : ASHTON, Michael, John [GB/GB]; COOK, David, Charles [GB/GB]; FEN- TON, Garry [GB/GB]; HILLS, Susan, Jacqueline [GB/ GB]; MCFARLANE, Ian, Michael [GB/GB]; PAL- FREYMAN, Malcolm, Norman [GB/GB]; RAT- CLIFFE, Andrew, James [GB/GB]; VICKER, Nigel [GB/GB]; Rhône-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB).</p>		<p>(74) Agents: BENTHAM, Stephen et al.; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB).</p> <p>(81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), CS, DE (Eu- ropean patent), DK (European patent), ES (European patent), FI, FR (European patent), GB (European pa- tent), GR (European patent), HU, IT (European patent), JP, KR, LU (European patent), MC (European patent), NL (European patent), NO, PL, RU, SE (European pa- tent), US.</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: BENZAMIDES



(57) Abstract

Benzamide derivatives of formula (I), wherein R¹ represents alkyl, R² represents alkyl or mono-, bi- or tricycloalkyl, R³ represents an optionally substituted phenyl, naphthyl or heterocyclyl group, and Z represents oxygen or sulphur, and when said heterocyclyl groups contain one or more nitrogen ring atoms, N-oxides thereof, and pharmaceutically acceptable salts thereof, possess useful pharmacological properties.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	ML	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NL	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

- 1 -

"BENZAMIDES"

This invention relates to therapeutically useful benzamide derivatives, to processes for their preparation, to pharmaceutical compositions containing them, and to methods for their use.

The present invention provides compounds of general formula I, hereinafter depicted, wherein R^1 represents a straight- or branched-chain alkyl group containing up to about 4 carbon atoms, R^2 represents a straight- or branched-chain alkyl group containing from about 2 to about 15, preferably 2 to 12, carbon atoms or a mono-, bi- or tricycloalkyl group containing up to about 10 carbon atoms, R^3 represents an optionally substituted phenyl, naphthyl or heterocyclyl group, preferably a 5-, 6- or 7-membered heterocyclyl group containing one or more hetero atoms selected from oxygen, sulphur and nitrogen atoms, the optional substituents being one or more substituents selected from halogen atoms, alkyl groups which may carry one or more halogen atoms, and from aryl, arylalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkoxycarbonyl, aryloxycarbonyl, alkanoyl, aroyl, alkylsulphonyl, arylsulphonyl, alkylsulphinyl, arylsulphinyl, hydroxy, hydroxyalkyl, formyl, alkanoylamino, aroylamino, cyano and nitro groups, and from amino, carbamoyl and sulphamoyl groups which themselves may each carry one

- 2 -

or two alkyl substituents, and Z represents an oxygen or sulphur atom, and when said heterocyclyl groups contain one or more nitrogen ring atoms, N-oxides thereof, and pharmaceutically acceptable salts thereof, wherein all aryl groups and moieties, unless otherwise indicated, are selected from phenyl and naphthyl groups optionally substituted by one or more substituents selected from halogen atoms and alkyl and alkoxy groups, and wherein all alkyl groups and moieties, unless otherwise indicated, are straight- or branched-chain and contain up to about 4 carbon atoms.

- 3 -

Especially important compounds of the invention include those wherein at least one of the symbols has a value selected from the following:-

- (i) R^1 represents a methyl group;
 - (ii) R^2 represents a propyl, butyl, nonyl, dodecyl, cyclohexyl, 8,9,10-trinorbornyl or, more especially, cyclopentyl group; and/or
 - (iii) R^3 represents an optionally substituted pyrazinyl, pyrimidinyl, isoxazolyl, preferably pyridyl group, or an N-oxide thereof, or an optionally substituted phenyl group;
- the other symbols being as hereinbefore defined.

Among compounds wherein R^3 represents a substituted phenyl group, compounds wherein said phenyl group is substituted in the 2-position or in the 2- and 6-positions are especially useful.

Similarly, among compounds wherein R^3 represents a substituted heterocyclyl group, compounds wherein said heterocyclyl group is substituted on one or both of the positions next to the point of attachment to the rest of the molecule are especially useful.

- 4 -

Individual compounds of especial importance include the following:-

- A N-(2,6-difluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- B N-(2-chloro-6-fluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- C N-(2-trifluoromethylphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- D N-(2,4,6-trichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- E N-(2,6-dibromophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- F N-(2-chloro-6-methylphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- G N-(2,6-dichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- H N-(2-fluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- I N-phenyl-3-cyclopentyloxy-4-methoxybenzamide,
- J N-(2-methoxyphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- K N-(2-chlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- L N-(3-chlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide

- 5 -

- M N-(4-methoxyphenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- N N-(2,6-dimethylphenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- O N-(2-methylthiophenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- P N-(2-bromophenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- Q N-(2-methoxycarbonylphenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- R N-(2-aminosulphonylphenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- S N-(2-benzoylphenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- T N-(2-cyanophenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- U N-(2,5-dichlorophenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- V N-(3-methylphenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- W N-(2-nitrophenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- X N-(2-dimethylaminophenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- Y N-(2-acetylphenyl)-3-cyclopentyloxy-4-methoxy-
benzamide

- 6 -

- Z N-(2-hydroxyphenyl)-3-cyclopentyloxy-4-methoxy-
benzamide
- AA N-(2-methylsulphonylphenyl)-3-cyclopentyloxy-4-
methoxybenzamide
- AB N-(2,6-difluorophenyl)-3-cyclohexyloxy-4-
methoxybenzamide
- AC N-(2,6-difluorophenyl)-3-butoxy-4-methoxy-
benzamide
- AD N-(2,6-difluorophenyl)-3-propoxy-4-methoxy-
benzamide
- AE N-(2-chlorophenyl)-3-cyclopentyloxy-4-methoxy-
(thiobenzamide)
- AF N-(4-chloropyrid-3-yl)-3-cyclopentyloxy-4-
methoxybenzamide
- AG N-pyrid-2-yl-3-cyclopentyloxy-4-methoxybenzamide
- AH N-pyrazin-2-yl-3-cyclopentyloxy-4-methoxy-
benzamide
- AI N-pyrimidin-2-yl-3-cyclopentyloxy-4-methoxy-
benzamide
- AJ N-(3-methylpyrid-2-yl)-3-cyclopentyloxy-4-
methoxybenzamide
- AK N-pyrid-3-yl-3-cyclopentyloxy-4-methoxybenzamide
- AL N-(3-chloropyrid-2-yl)-3-cyclopentyloxy-4-
methoxybenzamide
- AM N-(3-chloropyrid-4-yl)-3-cyclopentyloxy-4-
methoxybenzamide

- 7 -

- AN N-pyrid-4-yl-3-cyclopentyloxy-4-methoxybenzamide
- AO N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AP N-(3,5-dimethylisoxazol-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AQ N-(4,6-dichloropyrimid-5-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AR N-(4-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- AS N-(2,3,5,6-tetrafluoropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AT N-(3,5-dichloro-2,6-difluoropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AU N-(2,4,6-trifluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide
- AV 3,5-dichloro-4-(3-cyclopentyloxy-4-methoxybenzamido)pyridine-N-oxide
- AW N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide
- AX N-(3,5-dichloropyrid-4-yl)-3-cyclohexyloxy-4-methoxybenzamide
- AY N-(3,5-dibromopyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- AZ N-(3,5-dichloropyrid-4-yl)-3-butoxy-4-methoxybenzamide

- 8 -

- BA N-(3-methyl-5-bromoisothiazol-4-yl)-3-cyclopentyl-4-methoxybenzamide
- BB N-(3,5-dimethylisothiazol-4-yl)-3-cyclopentyl-4-methoxybenzamide
- BC N-(3,5-dimethylpyrid-4-yl)-3-cyclopentyl-4-methoxybenzamide
- BD N-(5-cyano-3-methylisothiazol-4-yl)-3-cyclopentyl-4-methoxybenzamide
- BE N-(3,5-dichloropyrid-4-yl)-3-cyclopentyl-4-methoxy(thiobenzamide)
- BF N-(2,6-dichloro-4-methoxyphenyl)-3-cyclopentyl-4-methoxybenzamide
- BG N-(2,6-dichloro-4-cyanophenyl)-3-cyclopentyl-4-methoxybenzamide
- BH N-(2,6-dichloro-4-carbamoylphenyl)-3-cyclopentyl-4-methoxybenzamide
- BI N-(2,6-dichloro-4-aminophenyl)-3-cyclopentyl-4-methoxybenzamide
- BJ N-(3-chloro-2,5,6-trifluoropyrid-4-yl)-3-cyclopentyl-4-methoxybenzamide
- BK N-(3,5-dibromopyrid-4-yl)-3-butoxy-4-methoxybenzamide
- BL N-(2,6-dichloro-4-methoxycarbonylphenyl)-3-cyclopentyl-4-methoxybenzamide
- BM N-(4-acetylamino-2,6-dichlorophenyl)-3-cyclopentyl-4-methoxybenzamide

- 9 -

- BN N-(3,5-dichloropyrid-4-yl)-3-nonyloxy-4-methoxybenzamide
- BO N-(2,6-dichloro-4-formylphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- BP N-(2,6-dichlorophenyl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide
- BQ N-(2,3,5-trifluoropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- BR sodium salt of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide
- BS N-(2,6-dichloro-4-ethoxycarbonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- BT N-(2,6-dichloro-4-hydroxymethylphenyl)-3-cyclopentyloxy-4-methoxybenzamide
- BU N-(3,5-dichloropyrid-4-yl)-3-dodecyloxy-4-methoxybenzamide
- BV (R)-N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide
- BW (S)-N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide
- BX N-(2,6-dichloro-4-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide

The letters A to BX are allocated to compounds for easy reference in this specification.

The compounds of general formula I and their pharmaceutically acceptable salts exhibit

- 10 -

pharmacological activity and accordingly are of use for the preparation of pharmaceutical compositions and in the treatment of humans and other animals. More especially, they are cyclic AMP phosphodiesterase inhibitors, in particular type IV cyclic AMP phosphodiesterase inhibitors, and thus the present invention provides compounds of general formula I and their pharmaceutically acceptable salts, and compositions containing compounds of general formula I and their pharmaceutically acceptable salts, which are of use in a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of cyclic AMP phosphodiesterase, for example, they are useful as bronchodilators and asthma-prophylactic agents and agents for the inhibition of eosinophil accumulation and of the function of eosinophils, e.g. for the treatment of inflammatory airways disease, especially reversible airway obstruction or asthma, and for the treatment of other diseases and conditions characterised by, or having an aetiology involving, morbid eosinophil accumulation. As further examples of conditions which can be ameliorated by the administration of inhibitors of cyclic AMP phosphodiesterase such as compounds of general formula

- 11 -

I there may be mentioned inflammatory diseases, such as atopic dermatitis, urticaria, allergic rhinitis, psoriasis, rheumatic arthritis, ulcerative colitis, Crohn's disease, adult respiratory distress syndrome and diabetes insipidus, other proliferative skin diseases such keratosis and various types of dermatitis, conditions associated with cerebral metabolic inhibition, such as cerebral senility, multi-infarct dementia, senile dementia (Alzheimer's disease), and memory impairment associated with Parkinson's disease, and conditions ameliorated by neuroprotectant activity, such as cardiac arrest, stroke, and intermittent claudication.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of cyclic AMP phosphodiesterase, for example conditions as hereinbefore described.

Compounds within the scope of the present invention exhibit positive pharmacological activities as demonstrated by the following tests which are believed to correlate to pharmacological activity in humans and other mammals.

- 12 -

Compounds of the invention at concentrations from about 10^{-9} M up to about 10^{-5} M produced about 50% inhibition of porcine aorta cyclic AMP phosphodiesterase.

Compounds of the invention at concentrations of about 10^{-7} M to about 10^{-4} M produced about 50% relaxation of guinea-pig tracheal strips, which had been contracted by treatment with spasmogens such as histamine and carbachol.

Compounds of the invention at intraperitoneal doses from about 1 to about 25 mg/kg or at oral doses from about 1 to about 50 mg/kg inhibited by about 50% the accumulation of eosinophils in the lungs of guinea-pigs.

Compounds of the invention at concentrations from about 10^{-8} M up to about 10^{-5} M produced about 50% inhibition of superoxide generation from eosinophils harvested from the peritoneal cavities of guinea-pigs.

Compounds of the invention at oral doses from about 1 to about 50 mg/kg administered 1 hour before challenge inhibited by about 50% ovalbumin- or PAF-induced hyperreactivity in guinea-pigs.

Bronchorelaxant activity was measured in in vivo tests in the anaesthetised guinea-pig according to the method of Dixon and Brodie [J. Physiol., 29, 97-173, (1903)] in which the effects on histamine-induced

- 13 -

bronchospasm and mean arterial blood pressure were determined.

Nebulised aerosols generated from aqueous solutions of compounds of the invention were each administered for one minute to the anaesthetised guinea-pigs.

Alternatively, dry powder formulations made up from compounds of the invention and lactose were blown into the airways of the anaesthetised guinea-pigs.

Compounds of the invention produced from about 30% up to about 90% decrease in bronchospasm when administered at effective doses of about 20-80 μ g, without any significant effect on blood pressure.

Compounds of the invention as oral doses of about 1 to about 50mg/kg, administered one hour before challenge, inhibited by at least 50% ovalbumin-induced eosinophilia in guinea-pigs, which is measured 24 hours after challenge.


Administered at doses of about 1 to about 50mg/kg orally or parenterally or at doses of about 20 to about 500 μ g intratracheally, compounds of the invention inhibit PAF or ovalbumin-induced microvascular leakage (measured using fluorescein isothiocyanate dextran) by up to 100% in guinea-pigs.

The value of the compounds of the invention is enhanced by their very low mammalian toxicity levels.

- 14 -

Compounds of formula (I) can be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature.

Thus, according to a feature of the present invention, compounds of general formula I, wherein R^1 , R^2 and R^3 are as hereinbefore defined and Z represents an oxygen atom, are prepared by the reaction of compounds of general formula II hereinafter depicted, wherein R^1 and R^2 are as hereinbefore defined and X^1 represents a halogen, e.g. bromine or, preferably, chlorine atom, with compounds of the general formula:-



III

wherein R^3 is as hereinbefore defined, preferably in the presence of a base, for example an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, an alkali metal hydride, e.g. sodium hydride, or an amine, preferably a tertiary amine, e.g. triethylamine or pyridine, optionally in an inert solvent, for example dichloromethane, dimethylformamide, or an ether, e.g. diethyl ether or tetrahydrofuran, preferably at a temperature from 0°C to the reflux temperature or at the melting point of the reaction mixture.

According to a further feature of the present invention, compounds of general formula I are prepared

- 15 -

by the reaction of compounds of general formula IV hereinafter depicted, wherein R^1 , R^3 and Z are as hereinbefore defined, with compounds of the general formula:-



wherein R^2 is as hereinbefore defined and X^2 represents a halogen, preferably bromine, atom, preferably in the presence of a base, for example an alkali metal hydride, e.g. sodium hydride, an alkali metal hydroxide or carbonate, e.g. sodium hydroxide or carbonate, or an amine, preferably a tertiary amine, e.g. triethylamine or pyridine, optionally in an inert solvent, for example dichloromethane, dimethylformamide, or an ether, e.g. diethyl ether or tetrahydrofuran, preferably at a temperature from 0°C to the reflux temperature.

According to a further feature of the present invention, compounds of general formula I are prepared by interconversion of other compounds of general formula I.

For example, compounds of general formula I wherein R^1 , R^2 and R^3 are as hereinbefore defined and Z represents a sulphur atom are prepared from compounds of general formula I wherein R^1 , R^2 and R^3 are as hereinbefore defined and Z represents an oxygen atom, by reaction with phosphorus pentasulphide or 2,4-bis(4-

- 16 -

methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide, preferably in a solvent such as pyridine or toluene, and preferably at a temperature from 0°C to the reflux temperature.

As another example, compounds of general formula I wherein R^1 and R^2 are as hereinbefore defined, Z represents an oxygen atom and R^3 contains an alkylsulphonyl, arylsulphonyl alkylsulphinyl or arylsulphinyl group are prepared by the oxidation of compounds of general formula I wherein R^1 and R^2 are as hereinbefore defined, Z represents an oxygen atom and R^3 contains an alkylthio or arylthio group, preferably by means of reaction with a peroxyacid, e.g. 3-chloroperbenzoic acid, preferably in an inert solvent, e.g. dichloromethane, preferably at or near room temperature.

As another example, compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R^3 contains a hydroxymethyl group are prepared by the reduction of compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined and R^3 contains an aryloxycarbonyl or, preferably, alkoxycarbonyl group, preferably by means of reaction with an alkali metal borohydride, preferably in an inert solvent, e.g.

- 17 -

tetrahydrofuran, preferably at or near room temperature.

As another example, compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R^3 contains a formyl group are prepared by the oxidation of compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined and R^3 contains a hydroxymethyl group, preferably by means of reaction with manganese dioxide, preferably in an inert solvent, e.g. dichloromethane, preferably at or above room temperature, more especially at the reflux temperature.

As another example, compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R^3 contains an amino group are prepared by the reduction of compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined and R^3 contains a nitro group, preferably by means of reaction with iron in acidic conditions, e.g. in acetic acid, preferably at or above room temperature, more especially at the reflux temperature.

As another example, compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R^3 contains an alkanoylamino or aroylamino group are prepared from

- 18 -

compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined and R^3 contains an amino group, preferably by means of reaction with the appropriate acid halide or acid anhydride, optionally in an inert solvent, and preferably at a temperature from 0°C to the reflux temperature.

As another example, N-oxides of compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined, Z preferably being an oxygen atom, and R^3 represents a heterocyclyl group containing one or more nitrogen ring atoms, are prepared by the oxidation of compounds of general formula I wherein R^1 , R^2 and Z are as hereinbefore defined and R^3 represents a heterocyclyl group containing one or more nitrogen ring atoms, preferably by means of reaction with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature at 60-90°C.

By the term "pharmaceutically acceptable salts" as used in this specification is meant salts the counter ions of which are relatively innocuous to the animal organism when used in therapeutic doses so that the beneficial pharmaceutical properties of the parent compounds of general formula I are not vitiated by side-effects ascribable to those counter ions.

- 19 -

Suitable acid addition salts for use in pharmaceuticals may be selected from salts derived from inorganic acids, for example hydrohalides, e.g. hydrochlorides and hydrobromides, phosphates, sulphates and nitrates, and organic acids, for example oxalates, lactates, tartrates, acetates, salicylates, citrates, propionates, succinates, fumarates, maleates, methylene-bis- β -hydroxynaphthoates, gentisates, mesylates, isethionates and di-p-toluoyltartrates.

As will be self-evident to those skilled in the art, some of the compounds of general formula I do not form stable salts. However, acid addition salts are most likely to be formed by compounds of formula I wherein

R^3 represents a nitrogen-containing heterocyclyl group and/or wherein R^3 contains an amino group as a substituent.

According to a further feature of the invention, acid addition salts of compounds of formula I are prepared by reaction of the parent compounds of formula I with the appropriate acid, by the application or adaptation of known methods.

Alkali and alkaline earth metal salts are also suitable for use in pharmaceuticals, especially sodium salts.

- 20 -

According to a further feature alkali and alkaline earth metal salts are prepared by reaction of the parent compounds of formula I with the appropriate base, by the application or adaptation of known methods. For example, sodium salts can conveniently be prepared by reaction with sodium hydride.

As well as being useful in themselves as active compounds, salts of compounds of formula I are useful for the purposes of purification of the parent compounds of formula I, for example by exploitation of the solubility differences between the salts and the parent compounds, by techniques well known to those skilled in the art.

The parent compounds of formula I can be regenerated from their salts by the application or adaptation of known methods.

For example, parent compounds of general formula I can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Similarly, parent compounds of general formula I can be regenerated from their alkali and alkaline earth metal salts by treatment with an acid, e.g. hydrochloric acid.

In this specification reference to compounds of formula I is intended to include reference to their

pharmaceutically acceptable salts, where the context so permits.

It will be apparent to those skilled in the art that certain compounds of general formula I can exhibit isomerism, for example optical isomerism. All isomers within general formula I, and their mixtures, are within the scope of the invention.

Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques, or they may be separately prepared from the appropriate isomers of their intermediates, for example by the application or adaptation of methods described herein.

The starting materials and intermediates can be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

For example, compounds of formula II can be prepared from compounds of general formula Va, hereinafter depicted, wherein R^1 and R^2 are as hereinbefore defined, by the application or adaptation of known methods for the preparation of acid halides from carboxylic acids. For example, when x^1 represents a chlorine atom, the reaction can be carried out by means of thionyl chloride.

-22-

Compounds of formula Va can be prepared by the oxidation of compounds of general formula VI, hereinafter depicted, wherein R^1 and R^2 are as hereinbefore defined, e.g. by means of reaction with potassium permanganate, or with a mixture of sulphamic acid and sodium chlorite in acetic acid.


Compounds of formula VI can be prepared from compounds of general formula VII, hereinafter depicted, wherein R^1 is as hereinbefore defined, by reaction with compounds of formula V as hereinbefore defined, or alternatively by reaction with compounds of the general formula:-




VIII

wherein R^2 is as hereinbefore defined, preferably in the presence of a compound such as diisopropyl azodicarboxylate.


- 23 -



I




II




IV


- 24 -



Va



VI



VII

- 25 -

The following Examples illustrate the preparation of the compounds according to the invention and the Reference Examples illustrate the preparation of the intermediates.

In the nuclear magnetic resonance spectra (NMR) the chemical shifts are expressed in ppm relative to tetramethylsilane. Abbreviations have the following significances:-

s = singlet; d = doublet; t = triplet; q = quartet;
m = multiplet; dd = doublet of doublets; b = broad.

EXAMPLE 1

Compounds A,B,C,D,E,F,G,H,I,J

K,L,M,N,O,P,Q,R,S,T,U,V,W,X,Y and Z

A stirred solution of 2,6-difluoroaniline (1.52g) and triethylamine (1.19g) in dichloromethane (50ml) at room temperature was treated with a solution of 3-cyclopentyloxy-4-methoxybenzoyl chloride (3.0g, prepared as described hereinafter in Reference Example 3) in dichloromethane (50ml), dropwise. The solution was stirred and heated at reflux for 4 hours, then it was cooled, washed with water and dried over magnesium sulphate. The solution was concentrated and the resulting residue was recrystallised from ethyl acetate, to give N-(2,6-difluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide (1.9g), m.p. 158-160°C [NMR(CDCl₃):- 1.55-1.7 (m, 3H), 1.8-2.05 (m, 5H), 3.93 (s, 3H), 4.85 (m, 1H),

- 26 -

6.9 (d, 1H), 6.95-7.03 (m, 2H), 7.2-7.3 (m, 1H), 7.35 (bs, 1H), 7.45 (q, 1H), 7.53 (d, 1H); Elemental analysis:- C, 65.1; H, 5.6; F, 10.4; N, 4.2%; Calculated:- C, 65.7; H, 5.5; F, 10.9; N, 4.0%].

By proceeding in a similar manner, but replacing the 2,6-difluoroaniline by the appropriate quantities of the corresponding aniline derivatives, there were prepared:-

N-(2-chloro-6-fluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 140-142°C [Elemental analysis:- C, 62.3; H, 5.2; Cl, 9.7; N, 3.6%; Calculated:- C, 62.7; H, 5.3; Cl, 9.75; N, 3.85%];

N-(2-trifluoromethylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 127-129°C [Elemental analysis:- C, 63.4; H, 5.5; F, 13.3; N, 3.3%; Calculated:- C, 63.3; H, 5.3; F, 15.0; N, 3.7%];

N-(2,4,6-trichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 173°C [Elemental analysis:- C, 55.2; H, 4.4; Cl, 26.4; N, 3.1; Calculated:- C, 55.0; H, 4.4; Cl, 25.6; N, 3.4%];

N-(2,6-dibromophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 133°C [Elemental analysis:- C, 48.5; H, 4.0; Br, 33.9; N, 2.85%; Calculated:- C, 48.6; H, 4.1; Br, 34.1; N, 3.0%];

N-(2-chloro-6-methylphenyl)-3-cyclopentyloxy-4-

- 27 -

methoxybenzamide, m.p. 138-140°C [Elemental analysis:- C, 66.3; H, 6.2; Cl, 10.3; N, 3.8%; Calculated:- C, 66.75; H, 6.2; Cl, 9.85; N, 3.9%];

N-(2,6-dichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 138-140°C [Elemental analysis:- C, 59.8; H, 5.1; Cl, 19.1; N, 3.3%; Calculated:- C, 60.0; H, 5.0; Cl, 18.65; N, 3.7%];

N-(2-fluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 137°C [Elemental analysis:- C, 69.3; H, 6.2; F, 5.7; N, 4.0%; Calculated:- C, 69.3; H, 6.1; F, 5.8; N, 4.25%];

N-phenyl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 169-173°C [Elemental analysis:- C, 73.2; H, 6.7; N, 4.2%; Calculated:- C, 73.3; H, 6.8; N, 4.5%];

N-(2-methoxyphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 132-134°C [Elemental analysis:- C, 70.1; H, 6.8; N, 4.0%; Calculated:- C, 70.4; H, 6.8; N, 4.1%];

N-(2-chlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 122-124°C [Elemental analysis:- C, 65.8; H, 5.8; Cl, 10.5; N, 3.9%; Calculated:- C, 66.0; H, 5.8; Cl, 10.25; N, 4.05%];

N-(3-chlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 110-112°C [Elemental analysis:- C, 65.9; H, 6.5; Cl, 9.8; N, 3.7%; Calculated:- C, 66.0; H, 5.8; Cl, 10.25; N, 4.05%];

N-(4-methoxyphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 182-184°C [Elemental analysis:- C, 68.7; H, 6.6; N, 3.8%; Calculated for $C_{20}H_{23}NO_4 \cdot \frac{1}{2}H_2O$:- C, 68.55; H, 6.9; N, 4.0%];

- 28 -

N-(2,6-dimethylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 130-131°C [Elemental analysis:- C, 74.2; H, 7.4; N, 4.1%; Calculated:- C, 74.3; H, 7.4; N, 4.13%];

N-(2-methylthiophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 128-130°C [Elemental analysis:- C, 67.6; H, 6.5; N, 3.9; S, 8.9%; Calculated:- C, 67.2; H, 6.5; N, 3.9; S, 9.0%];

N-(2-bromophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 126-128°C [Elemental analysis:- C, 58.2; H, 5.1; Br, 20.4; N, 3.5%; Calculated:- C, 58.5; H, 5.2; Br, 20.5; N, 3.6%];

N-(2-methoxycarbonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 105-107°C [Elemental analysis:- 68.4; H, 6.35; N, 3.7%; Calculated:- 68.3; 6.3; N, 3.8%];

N-(2-aminosulphonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 248°C [Elemental analysis:- C, 58.0; H, 5.5; N, 6.9%; Calculated:- C, 58.45; H, 5.7; N, 7.2%];

N-(2-benzoylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 106-107°C [Elemental analysis:- C, 75.5; H, 6.3; N, 3.3%; Calculated:- C, 75.2; H, 6.1; N, 3.4%];

N-(2-cyanophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 170-172°C [Elemental analysis:- C, 71.0; H, 6.0; N, 8.1%; Calculated:- C, 75.2; H, 6.1; N, 3.4%];

N-(2,5-dichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 117-119°C [Elemental analysis:- C, 59.7; H, 5.0; Cl, 18.5; N, 3.7%; Calculated:- C, 60.0; H, 5.0;

- 29 -

Cl, 18.65; N, 3.7%];

N-(3-methylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 147-149°C [Elemental analysis:- C, 73.8; H, 7.1; N, 4.2%; Calculated:- C, 73.8; H, 7.1; N, 4.3%];

N-(2-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 130-132°C [Elemental analysis:- C, 64.0; H, 5.7; N, 7.4%; Calculated:- C, 64.0; H, 5.7; N, 7.9%];

N-(2-dimethylaminophenyl)-3-cyclopentyloxy-4-methoxybenzamide, in the form of a brown oil [Elemental analysis:- C, 71.5; H, 7.4; N, 7.4%; Calculated:- C, 71.2; H, 7.4; N, 7.9%];

N-(2-acetylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 126-127°C [Elemental analysis:- C, 71.0; H, 6.6; N, 3.9%; Calculated:- C, 71.4; H, 6.6; N, 4.0%]; and

N-(2-hydroxyphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 169-171°C [Elemental analysis:- C, 69.5; H, 6.5; N, 3.9%; Calculated:- C, 69.7; H, 6.5; N, 4.3%].

EXAMPLE 2

Compound AA

A stirred solution of N-(2-methylthiophenyl)-3-cyclopentyloxy-4-methoxybenzamide (1.80g; prepared as described hereinbefore in Example 1) was treated with a solution of 3-chloroperbenzoic acid (3.60g; 85% pure) in dichloromethane (72ml), dropwise, and then it was stirred at room temperature for 5 hours. The reaction mixture was washed with saturated aqueous

- 30 -

sodium bicarbonate solution and then with water, and then it was dried over magnesium sulphate. Concentration gave N-(2-methylsulphonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, (1.12g), in the form of a white solid, m.p. 119-121°C [NMR(CDCl₃):- 1.52-2.16 (m, 8H), 3.1 (s, 3H), 3.94 (s, 3H), 4.9 (m, 1H), 6.96 (d, 1H), 7.46 (m, 1H), 7.6 (m, 2H), 7.7 (t, 1H), 7.95 (d, 1H), 8.68 (d, 1H); Elemental analysis:- C, 61.6; H, 6.0; N, 3.5; S, 8.5%; Calculated:- C, 61.7; H, 5.95; N, 3.6; S, 8.5%].

EXAMPLE 3

Compounds AB, AC and AD

By proceeding in a manner similar to that described hereinbefore in Example 1, but using the appropriate quantities of the corresponding acid chlorides, prepared as described hereinafter in Reference Example 3, there were prepared:-

N-(2,6-difluorophenyl)-3-cyclohexyloxy-4-methoxybenzamide, m.p. 60°C [Elemental analysis:- C, 66.1; H, 6.3; N, 3.3%; Calculated:- C, 66.5; H, 5.9; N, 3.9%];

N-(2,6-difluorophenyl)-3-butoxy-4-methoxybenzamide, m.p. 150-152°C. [Elemental analysis:- C, 64.6; H, 5.8; N, 4.2; Calculated:- C, 64.5; H, 5.7; N, 4.2%]; and

N-(2,6-difluorophenyl)-3-propoxy-4-methoxybenzamide, m.p. 170-174°C. [Elemental analysis:- C, 63.4; H, 5.4; N, 4.4%; Calculated:- C, 63.5; H, 5.3; N, 4.4%].

- 31 -

EXAMPLE 4Compound AE

3-Cyclopentyloxy-4-methoxybenzoyl chloride (13.3g) and 2-chloroaniline (6.6g) were dissolved in pyridine (50ml) and the solution was allowed to stand at room temperature for 1 hour. Phosphorus pentasulphide (13g) was added and the stirred mixture was heated at 110°C for 1.5 hours. After cooling to room temperature the mixture was poured into an ice-cold solution of concentrated hydrochloric acid (100ml) in water (400ml). The mixture was stirred for 1 hour and the yellow solid was collected, washed with water and subjected to flash chromatography on silica gel, eluting with a mixture of cyclohexane and ethyl acetate (3:1v/v), to give N-(2-chlorophenyl)-3-cyclopentyloxy-4-methoxy(thiobenzamide) (5.4g), m.p. 129-131°C [Elemental analysis:- C, 62.6; H, 5.5; N, 3.9; S, 8.9%; Calculated:- C, 63.1; H, 5.6; N, 3.9; S, 8.9%].

EXAMPLE 5Compounds AF, AG, AH, AI, AJ, AK AL, AM and AN

A stirred solution of 4-chloropyrid-3-ylamine (1.94g) and 3-cyclopentyloxy-4-methoxybenzoyl chloride (3.85g) in pyridine (50ml) was heated at 80°C for 7 hours and then it was allowed to stand overnight. The reaction mixture was evaporated, to give a brown

- 32 -

oil, which was subjected to mplc on silica gel, using diethyl ether as eluent, to give N-(4-chloropyrid-3-yl)-3-cyclopentyloxy-4-methoxybenzamide (3.1g), m.p. 130-132°C.

By proceeding in a similar manner, but using the appropriate quantities of the appropriate amines instead of the 4-chloropyrid-3-ylamine used as a starting material, there were prepared:-

N-pyrid-2-yl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 92-94°C;

N-pyrazin-2-yl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 80-82°C;

N-pyrimidin-2-yl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 108-110°C;

N-(3-methylpyrid-2-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 55°C;

N-pyrid-3-yl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 170-172°C;

N-(3-chloropyrid-2-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 138-140°C;

N-(3-chloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 124-126°C

N-pyrid-4-yl-3-cyclopentyloxy-4-methoxybenzamide, m.p. 163-165°C.

- 33 -

EXAMPLE 6Compound AO

4-Amino-3,5-dichloropyridine (4.0g) and 3-cyclopentyloxy-4-methoxybenzoyl chloride (6.26g) were intimately ground together in a mortar with a pestle, and transferred to a round-bottomed flask. The mixture was melted, using a hot air gun external to the flask, stirring with a magnetical stirrer. After 10 minutes, heating was ceased and the melt was allowed to cool. The resulting material was triturated with dichloromethane and the residual solid was filtered off. The filtrate was concentrated to give a fawn solid, which was subjected to flash chromatography on silica gel, eluting with diethyl ether, to give N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide (1.87g), m.p. 155-157°C. [Elemental analysis: C, 56.3; H, 4.7; N, 7.2; Cl, 18.4%; calculated: C, 56.7; H, 4.76; N, 7.35; Cl, 18.6%; IR spectrum:- 1661cm^{-1} , 3244cm^{-1}].

- 34 -

EXAMPLE 7Compound AP

By proceeding in a manner similar to that described hereinbefore in Example 1, but replacing the 2,6-difluoroaniline used as a starting material by the appropriate quantity of 4-amino-3,5-dimethylisoxazole, there was prepared N-(3,5-dimethylisoxazol-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 150-152°C. [Elemental analysis: C, 65.6; H, 6.8; N, 8.5%; calculated: C, 65.4; H, 6.7; N, 8.5%].

- 35 -

EXAMPLE 8Compounds AO, AY, BC, BG, BL, BO, BS, BX, AX, AZ, AW, BV and BW

A suspension of sodium hydride (60% dispersion in oil; 2.2g) in dry tetrahydrofuran (25ml) at 15-20°C was treated portionwise with a solution of 4-amino-3,5-dichloropyridine (4.5g; prepared as described in Reference Example 5) in dry tetrahydrofuran (40ml), with cooling. The mixture was stirred for a further 30 minutes, and then it was cooled to 10°C and treated with a solution of 3-cyclopentyloxy-4-methoxybenzoyl chloride (6.4g) in dry tetrahydrofuran (40ml), dropwise, during 45 minutes at 10°C. The mixture was stirred at 10°C for 30 minutes and was then treated with dilute hydrochloric acid (50ml; 1N), followed by dichloromethane (75ml). The layers were separated and the aqueous layer was washed with a further quantity of dichloromethane (25ml). The combined organic layers were washed with water (50ml), with saturated aqueous sodium bicarbonate solution (100ml), and with water (50ml), dried over magnesium sulphate and evaporated to dryness. The resulting residue was recrystallised from isopropanol, to give N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide (7.0g).

By proceeding in a similar manner, but replacing the 4-amino-3,5-dichloropyridine used as a starting

- 36 -

material by the appropriate quantities of the appropriate amines, and optionally using dimethylformamide instead of tetrahydrofuran, there were prepared:-

N-(3,5-dibromopyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 160-162°C [Elemental analysis:- C,46.4;H,3.9;N,6.1%; calculated:- C,46.0;H,3.9;N,6.0%];

N-(3,5-dimethylpyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 77-80°C [Elemental analysis:- C,67.2;H,6.9;N,7.8%; calculated:- C,67.0;H,7.3;N,7.8%];

N-(2,6-dichloro-4-cyanophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 170-172°C [Elemental analysis:- C,59.1;H,4.5;N,7.0;Cl,17.5%; calculated:- C,59.3;H,4.5;N,6.9;Cl,17.5%];

N-(2,6-dichloro-4-methoxycarbonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 158-160°C [Elemental analysis:- C,57.4;H,4.9;N,3.2;Cl,16.4%; calculated:- C,57.5;H,4.8;N,3.2;Cl,16.2%];

N-(2,3,5-trifluoropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 144-146°C [Elemental analysis:- C,59.3;H,4.9;N,7.5%; calculated:- C,59.0;H,4.7;N,7.65%];

N-(2,6-dichloro-4-ethoxycarbonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 164-166°C;

N-(2,6-dichloro-4-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 154-156°C;

- 37 -

N-(3,5-dichloropyrid-4-yl)-3-cyclohexyloxy-4-methoxybenzamide, m.p. 170°C [Elemental analysis:- C,57.8; H,5.1;N,7.0;Cl,17.8%; calculated:- C,57.7;H,5.1;N,7.1; Cl,17.9%];

N-(3,5-dichloropyrid-4-yl)-3-butoxy-4-methoxybenzamide, m.p. 165-167°C [Elemental analysis:- C,55.1;H,4.8; N,7.6;Cl,19.2%; calculated:- C,55.3;H,4.9;N,7.6; Cl,19.2%];

N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide, m.p. 149-150°C [Elemental analysis:- C,58.8;H,4.9;N,6.7%; calculated:- C,59.0; H,5.0;N,6.9%];

(R)-N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide, m.p. 155-156°C [Elemental analysis:- C,58.8;H,5.0;N,6.8%]; and

(S)-N-(3,5-dichloropyrid-4-yl)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide, m.p. 156-157°C.

EXAMPLE 9

Compound AV

A stirred suspension of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide (2.0g; prepared as described in Example 6) in glacial acetic acid (8ml) was treated with an aqueous solution of hydrogen peroxide (6ml;27.5%). The mixture was stirred for 3 hours at 70-80°C and then it was treated with a further portion of hydrogen peroxide solution (4ml), and the

- 38 -

solution was stirred for a further 12 hours. The solution was then cooled, basified by treatment with concentrated aqueous sodium hydroxide solution, and extracted with dichloromethane (2x30ml). The organic extract was washed with brine (30ml), dried over magnesium sulphate and evaporated. The resulting residue was recrystallised from ethyl acetate, to give 3,5-dichloro-4-(3-cyclopentyloxy-4-methoxybenzamido)-pyridine-N-oxide (0.73g), m.p. 118-120°C [Elemental analysis:-C,53.0;H,4.4;N,6.8%; calculated for $C_{18}H_{18}O_4N_2Cl_2 \cdot 0.5H_2O$:- C,53.2;H,4.7;N,6.9%].

EXAMPLE 10

Compound BE

A stirred solution of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide (2.0g; prepared as described in Example 6) in toluene (50ml) was treated with 2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulphide (3.0g), and the mixture was heated at 100°C for 2 hours. After cooling to room temperature and filtration, the filtrate was concentrated in vacuo, to give a yellow oil. This oil was subjected to flash chromatography on silica gel, using a mixture of pentane and ethyl acetate (8:2v/v) as eluent, to give N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxy(thiobenzamide) (0.64g) m.p. 118-119°C [Elemental analysis:- C,54.1;H,4.6;Cl,17.4;

- 39 -

N, 6.8%; calculated:- C, 54.4; H, 4.6; Cl, 17.85; N, 7.05%].

EXAMPLE 11

Compound BI

A solution of N-(2,6-dichloro-4-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide (1.5g; prepared as described in Example 8) in glacial acetic acid (22ml) was treated with iron pin dust (1.3g) and the mixture was heated with stirring at 90°C for 1 hour. The reaction mixture was cooled, basified to pH8 by treatment with saturated aqueous sodium carbonate solution, and extracted with ethyl acetate (2 x 150ml). The combined organic extract was dried over magnesium sulphate and concentrated in vacuo, to give a white solid. This solid was subjected to flash chromatography, eluting with a mixture of ethyl acetate and pentane (1:1v/v), to give N-(2,6-dichloro-4-amino-phenyl)-3-cyclopentyloxy-4-methoxybenzamide (0.8g), m.p. 170-172°C [Elemental analysis:- C, 54.8; H, 5.04; N, 6.5; Cl, 17.4%; calculated:- C, 57.7; H, 5.1; N, 7.1; Cl, 17.9%].

EXAMPLE 12

Compound BM

Acetic anhydride (10ml) was treated with N-(2,6-dichloro-4-aninophenyl)-3-cyclopentyloxy-4-methoxybenzamide (0.8g; prepared as described in Example 11), and the reaction mixture was stirred for 2

- 40 -

hours and left to stand overnight. It was then poured into water (100ml), and extracted with ethyl acetate (100ml) and then with dichloromethane (100ml). The organic extracts were combined, dried over magnesium sulphate, and evaporated, to give N-(4-acetylamino-2,6-dichlorophenyl)-3-cyclopentyloxy-4-methoxybenzamide (0.4g), m.p. 250-252°C [Elemental analysis:- C,57.6;H,5.05;N,6.3;Cl,16.1%; calculated:- C,57.5;H,5.1;N,6.4;Cl,16.2%].

EXAMPLE 13

Compounds BN and BU

A stirred solution of N-(3,5-dichloropyrid-4-yl)-3-hydroxy-4-methoxybenzamide (2.0g; prepared as described in Reference Example 12) in dimethylformamide (20ml) at room temperature under nitrogen was treated portionwise with a suspension of sodium hydride (60% dispersion in oil; 0.26g), and then it was stirred for a further hour at room temperature. It was then treated dropwise with 1-bromononane (1.2ml) and stirred at 60°C for 5 hours. The solution was then cooled to room temperature, diluted with water (60ml), and extracted with ethyl acetate (2x100ml). The combined organic extracts were dried over magnesium sulphate and evaporated, to give a white solid, which was subjected to flash chromatography on silica gel, eluting with t-butyl methyl ether, to give N-(3,5-dichloropyrid-4-

- 41 -

yl)-3-nonyloxy-4-methoxybenzamide (0.56g), m.p. 151-153°C [Elemental analysis:- C, 60.3; H, 6.45; N, 6.3%; calculated:- C, 60.1; H, 6.4; N, 6.4%].

By proceeding in a similar manner, but using the appropriate quantity of 1-bromododecane, there was prepared N-(3,5-dichloropyrid-4-yl)-3-dodecyloxy-4-methoxybenzamide, m.p. 143-145°C.

EXAMPLE 14

Compound BO

A solution of N-(2,6-dichloro-4-hydroxymethyl-phenyl)-3-cyclopentyloxy-4-methoxybenzamide (4.4g) in dichloromethane (30ml) was treated with activated manganese dioxide (6.2g), and the mixture was stirred at reflux for 24 hours. The mixture was filtered, the filtrate was evaporated, and the resulting residue was subjected to flash chromatography on silica gel, eluting with ethyl acetate, to give N-(2,6-dichloro-4-formylphenyl)-3-cyclopentyloxy-4-methoxybenzamide (2.4g), m.p. 96-98°C [Elemental analysis:- C, 59.0; H, 5.1; N, 3.1%; calculated:- C, 58.8; H, 4.7; N, 3.4%].

EXAMPLE 15

Compound BT

A stirred solution of N-(2,6-dichloro-4-ethoxy-carbonylphenyl)-3-cyclopentyloxy-4-methoxybenzamide (6.1g; prepared as described in Example 8) in dry tetrahydrofuran (80ml) at room temperature under argon

- 42 -

was treated dropwise with a solution of lithium borohydride in tetrahydrofuran (115ml; 2M). The mixture was stirred overnight and then it was treated portionwise with saturated brine (200ml) and stirred for 30 minutes. The organic layer was then washed with water, dried over magnesium sulphate and evaporated. The resulting residue was subjected to flash chromatography on silica gel, to give N-(2,6-dichloro-4-hydroxymethylphenyl)-3-cyclopentyl-oxy-4-methoxybenzamide (4.4g), m.p. 174-176°C [Elemental analysis:- C, 57.1; H, 5.4; N, 2.9%; calculated for $C_{20}H_{21}O_4NCl_2 \cdot 0.5H_2O$:- C, 57.3; H, 5.3; N, 3.3%].

EXAMPLE 16

Compound BR

A solution of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyl-oxy-4-methoxybenzamide (3.8g; prepared as described in Example 6) in dry tetrahydrofuran (25ml) was treated with a suspension of sodium hydride (60% dispersion in oil; 0.40g), and the mixture was stirred until effervescence had ceased and a solution had formed. This solution was evaporated in vacuo and the resulting residue was triturated with t-butyl methyl ether (20ml). The resulting off-white solid was filtered off, quickly washed with t-butyl methyl ether (2x20ml) and dried, to give the sodium salt of N-(3,5-dichloropyrid-4-yl)-3-cyclopentyl-oxy-4-methoxy-

- 43 -

benzamide (3.5g), m.p. 265-270°C (with decomposition)
[NMR(DMSO-D₆):- 1.52-1.93(m,8H),4.77(s,3H),4.75-4.80
(m,1H),6.98(d,1H),7.58(dd,1H),7.60(s,1H),8.20(s,2H);
IR spectrum:- strong peak at 1508cm⁻¹, with no peaks at
or near 1661cm⁻¹ nor 3244cm⁻¹, which would have been
characteristics of the starting material].

EXAMPLE 17

Compounds AU, BF and BP

By proceeding in a manner similar to that
described in Example 5, but replacing the
4-chloropyrid-3-ylamine used as a starting material by
the appropriate quantities of the corresponding aniline
derivatives, there were prepared:-

N-(2,4,6-trifluorophenyl)-3-cyclopentyloxy-4-methoxy-
benzamide, m.p. 160-162°C [Elemental analysis:- C,62.5;
H,5.0;N,3.6%; calculated:- C,62.5;H,5.0;N,3.8%]; and
N-(2,6-dichloro-4-methoxyphenyl)-3-cyclopentyloxy-4-
methoxybenzamide, m.p. 126-128°C [Elemental analysis:-
C,57.9;H,4.9;N,3.2%; calculated:- C,58.5;H,5.2;N,3.4%].

By again proceeding in a similar manner, but
replacing the 4-chloropyrid-3-ylamine and the
3-cyclopentyloxy-4-methoxybenzoyl chloride by the
appropriate quantities of 2,6-dichloroaniline and
3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzoyl
chloride (prepared as described in Reference Example
14), there was prepared N-(2,6-dichlorophenyl)-3-(exo-

- 44 -

8,9,10-trinorbornyl-2-oxy)-4-methoxybenzamide, m.p.
106-107°C [Elemental analysis:- C,61.8;H,5.2;N,3.2%;
calculated:- C,62.1;H,5.2;N,3.45%].

EXAMPLE 18

Compounds AQ, AS, AT, BD, BH, BJ and BK

By proceeding in a manner similar to that described in Example 6, but replacing the 4-amino-3,5-dichloropyridine used as a starting material by the appropriate quantities of the corresponding amines, there were prepared:-

N-(4,6-dichloropyrimid-5-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 191-193°C [Elemental analysis:- C,53.1;H,4.4;Cl,18.6;N,10.9%; calculated:- C,53.1;H,4.5;Cl,18.6;N,10.8%];

N-(2,3,5,6-tetrafluoropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 178-180°C [Elemental analysis:- C,56.0;H,4.1;N,7.2%; calculated:- C,56.25;H,4.2;N,7.3%];

N-(3,5-dichloro-2,6-difluoropyrid-4-yl)-3-cyclopentyl-oxy-4-methoxybenzamide, m.p. 188-190°C [Elemental analysis:- C,51.5;H,3.8;N,6.8;Cl,17.0%; calculated:- C,51.8;H,3.9;N,6.7;Cl,17.0%];

N-(5-cyano-3-methylisothiazol-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 163-164°C [Elemental analysis:- C,60.0;H,5.3;N,11.7%; calculated:- C,60.5;H,5.85;N,11.8%];

- 45 -

N-(2,6-dichloro-4-carbamoylphenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 245-247° [Elemental analysis:- C, 54.0; H, 4.5; N, 6.4%; calculated:- C, 54.4; H, 5.0; N, 6.35%]; and

N-(3-chloro-2,5,6-trifluoropyrid-4-yl)-3-cyclopentyl-oxy-4-methoxybenzamide, m.p. 188-190°C [Elemental analysis:- C, 53.7; H, 3.95; N, 6.81; Cl, 8.9%; calculated:- C, 53.94; H, 4.0; N, 7.0; Cl, 8.85%].

By again proceeding in a similar manner, but replacing the 4-amino-3,5-dichloropyridine and the 3-cyclopentyloxy-4-methoxybenzoyl chloride by the appropriate quantities of 4-amino-3,5-dibromopyridine and 3-butoxy-4-methoxybenzoyl chloride (prepared as described in Reference Example 3), there was prepared N-(3,5-dibromopyrid-4-yl)-3-butoxy-4-methoxybenzamide, m.p. 160-162°C [Elemental analysis:- C, 44.6; H, 3.9; N, 6.1%; calculated:- C, 44.6; H, 4.0; N, 6.1%].

EXAMPLE 19

Compounds AR, BA and BB

By proceeding in a manner similar to that described in Example 1, but replacing the 2,6-difluoro-aniline used as starting material by the appropriate quantities of the corresponding amines, there were prepared:-

N-(4-nitrophenyl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 178-180°C [Elemental analysis:- C, 64.1; H, 5.7;

- 46 -

N,7.5%; calculated:- C,64.0;H,5.7;N,7.9%];

N-(3-methyl-5-bromoisothiazol-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 160-162°C [Elemental analysis:- C,50.0;H,4.7;N,6.8%; calculated:- C,49.6;H,4.7;N,6.8%]; and

N-(3,5-dimethylisothiazol-4-yl)-3-cyclopentyloxy-4-methoxybenzamide, m.p. 140-141°C [Elemental analysis:- C,62.4;H,6.35;N,8.0%; calculated:- C,62.4;H,6.4;N,8.1%].

- 47 -

REFERENCE EXAMPLE 1

A stirred solution of 3-hydroxy-4-methoxybenzaldehyde (2.00g) in dry dimethylformamide (20ml) was treated portionwise with sodium hydride (60% in oil; 0.56g) and the mixture was then heated for 1 hour at 50°C. It was then treated dropwise with cyclopentyl bromide (2.36g) and was stirred and heated at 50°C for 22 hours. The solution was diluted with water (100ml) and extracted with diethyl ether (2x100ml). The ethereal extracts were combined, dried over magnesium sulphate and concentrated, to give 3-cyclopentyloxy-4-methoxybenzaldehyde (1.65g) in the form of a golden oil.

By proceeding in a similar manner, but using the appropriate quantities of cyclohexyl bromide, butyl bromide and propyl bromide, respectively, there were prepared:-

3-cyclohexyloxy-4-methoxybenzaldehyde in the form of a golden oil [Elemental analysis:- C,71.8;H,7.8%;

Calculated:- C,71.8;H,7.7%];

3-butoxy-4-methoxybenzaldehyde in the form of a light brown oil [NMR(CDCl₃):- 1.0(t,3H), 1.5(m,2H), 1.9(m,2H), 3.96(s,3H), 4.1(t,2H), 6.96(d,1H), 7.4(m,2H), 9.8(s,1H)];

and 3-propoxy-4-methoxybenzaldehyde [NMR(CDCl₃):- 9.85(s,1H), 7.4(dd,1H), 7.4(d,1H), 7.0(d,1H), 4.05(t,2H), 4.0(s,3H), 1.9(m,2H), 1.06(t,3H)].

- 48 -

REFERENCE EXAMPLE 2

A stirred saturated aqueous solution of potassium permanganate (100ml) was treated with 3-cyclopentyloxy-4-methoxybenzaldehyde (7.4g; prepared as described hereinbefore in Reference Example 1) and sodium carbonate (3.4g) and the mixture was stirred at 50°C for 1 hour, and then cooled to room temperature. The reaction mixture was acidified by treatment with concentrated hydrochloric acid and then it was treated with aqueous sodium bisulphite solution until a colourless solution was obtained. The reaction mixture was extracted with dichloromethane (2x100ml) and the organic extracts were dried over magnesium sulphate and concentrated. The resulting residue was recrystallised from diethyl ether, to give 3-cyclopentyloxy-4-methoxybenzoic acid (4.78g) in the form of white crystals. [NMR(CDCl₃):- 1.7(s,2H),1.8-2.2(m,6H),3.95(s,3H),4.85(s,1H),6.9(bs,1H)7.6(bs,1H),7.8(s,1H),9.8(s,1H); Elemental analysis:- C,65.6; H,6.8%; Calculated:- C,66.1;H,6.8%].

By proceeding in a similar manner, but using the appropriate quantities of the corresponding benzaldehyde derivatives, prepared as described hereinbefore in Reference Example 1, there were prepared:-

- 49 -

3-cyclohexyloxy-4-methoxybenzoic acid in the form of a white solid, m.p. 158-160°C [NMR(CDCl₃):- 1.2-2.1 (m, 10H), 3.94 (s, 3H), 4.3 (m, 1H), 6.9 (d, 1H), 7.6 (s, 1H), 7.75 (d, 1H)];

3-butoxy-4-methoxybenzoic acid in the form of a white solid, m.p. 130-132°C [NMR(CDCl₃):- 1.0 (t, 3H), 1.5 (m, 2H), 1.85 (m, 2H), 3.95 (s, 3H), 4.1 (t, 2H), 6.92 (d, 2H), 7.6 (s, 1H), 7.75 (d, 1H)]; and

3-propoxy-4-methoxybenzoic acid [(NMR(CDCl₃):- 7.76 (dd, 1H), 7.6 (d, 1H), 6.9 (d, 1H), 4.04 (t, 2H), 3.94 (s, 3H), 1.9 (m, 2H), 1.05 (t, 3H)].

REFERENCE EXAMPLE 3

Stirred thionyl chloride (20ml) was treated with 3-cyclopentyloxy-4-methoxybenzoic acid (5.0g; prepared as described hereinbefore in Reference Example 2) portionwise and the solution was then heated at 85°C for 3 hours. Toluene (50ml) was added and the mixture was concentrated to give 3-cyclopentyloxy-4-methoxybenzoyl chloride (4.12g) in the form of an oil which slowly crystallised. [NMR(CDCl₃):- 1.6-1.7 (m, 2H), 1.8-1.95 (m, 4H), 1.94-2.05 (m, 2H), 3.94 (s, 3H), 4.85 (m, 1H), 6.9 (d, 1H), 7.55 (d, 1H), 7.8 (q, 1H); Elemental analysis:- C, 61.3; H, 5.94; Cl, 13.9%; Calculated:- C, 61.3; H, 5.94; Cl, 13.92%].

By proceeding in a similar manner, but using the appropriate quantities of the corresponding benzoic

- 50 -

acid derivatives, prepared as described hereinbefore in Reference Example 2, there were prepared:-

3-cyclohexyloxy-4-methoxybenzoyl chloride in the form of a colourless solid;

3-butoxy-4-methoxybenzoyl chloride in the form of a light brown oil; and

3-propoxy-4-methoxybenzoyl chloride [(NMR(CDCl₃):- 7.82 (dd, 1H), 7.53 (d, 1H), 6.92 (d, 1H), 4.03 (t, 2H), 3.96 (s, 3H), 1.89 (m, 2H), 1.06 (t, 3H)].

REFERENCE EXAMPLE 4

A stirred solution of 4-aminopyridine (40g) in concentrated hydrochloric acid (500ml) at 80°C. was treated dropwise with aqueous hydrogen peroxide solution (200ml; 15%w/w), keeping the temperature between 80°C. and 85°C. The solution was then cooled and basified by dropwise treatment with aqueous sodium hydroxide solution (50%w/w), keeping the temperature below 15°C. The resulting white flocculent precipitate was recrystallised from toluene, to give 4-amino-3,5-dichloropyridine (61.5g), m.p. 161.5-162.5°C.

- 51 -

REFERENCE EXAMPLE 5

A solution of 4-aminopyridine (47g) in concentrated hydrochloric acid (355ml) was treated portionwise at 80°C with an aqueous solution of sodium hypochlorite (550ml; 15% w/v). The mixture was cooled to 30°C and basified by treatment with aqueous sodium hydroxide solution (300ml; 35% w/v) during 20 minutes. The mixture was stirred and cooled for a further 30 minutes and then it was filtered. The solid was washed well with water and dried at 60°C, to give 4-amino-3,5-dichloropyridine (69.5g).

REFERENCE EXAMPLE 6

A solution of 3-cyclopentyloxy-4-methoxybenzaldehyde (66g) and sulphamic acid (39.6g) in glacial acetic acid (500ml) was treated dropwise during 1 hour with a solution of sodium chlorite (35g) in water (150ml). The mixture was stirred at 20°C during 1 hour and then it was treated with water (500ml) dropwise during 30 minutes. The resulting solid was filtered, washed with water and dried, to give 3-cyclopentyloxy-4-methoxybenzoic acid (60.9g) in the form of white crystals [Elemental analysis: - C, 65.8; H, 6.7%; calculated: - C, 66.1; H, 6.8%].

REFERENCE EXAMPLE 7

A solution of triphenylphosphine (17.5g) in dry tetrahydrofuran (50ml) under nitrogen was treated with

- 52 -

a solution of diisopropyl azodicarboxylate (13.5g) in dry tetrahydrofuran (50ml). The solution was stirred was treated with a solution of endo-8,9,10-trinor-borneol (5.0g) in dry tetrahydrofuran (50ml) followed by a solution of 3-hydroxy-4-methoxybenzaldehyde (10.2g) in dry tetrahydrofuran (50ml). The solution was heated at reflux for 15 hours, cooled, poured into water (600ml), and extracted with diethyl ether (300ml). The extract was washed with water (100ml), with aqueous sodium hydroxide solution (2x100ml;1M) and with water (2x100ml), dried over magnesium sulphate and evaporated, to give an oil, which was subjected to flash chromatography on silica gel, eluting with a mixture of pentane and ethyl acetate (95:5v/v) to give 3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzaldehyde (8.2g), m.p. 56-61°C.

REFERENCE EXAMPLE 8

A stirred suspension of 3-hydroxy-4-methoxybenzaldehyde (50g) in water (200ml) at between 0 and 5°C was treated dropwise with an aqueous solution of sodium hydroxide (200ml;20%w/v), followed at between 0 and 5°C by benzoyl chloride (38ml). The reaction mixture was stirred at between 0 and 5°C for 1 hour and then it was allowed to warm to room temperature and was stirred for a further period of 2 hours. The resulting solution was extracted with dichloromethane (2x200ml) and the

- 53 -

combined extract was washed with water (200ml), dried over magnesium sulphate and concentrated, to give 2-methoxy-5-formylphenyl benzoate (35.2g), m.p. 70-72°C.

REFERENCE EXAMPLE 9

A stirred solution of potassium permanganate (28g) in acetone (200ml) was treated with 2-methoxy-5-formylphenyl benzoate (35.2g; prepared as described in Reference Example 8), and the resulting vigorously reacting mixture was cooled in an ice bath. It was then stirred at room temperature for 3 hours. The mixture was then concentrated and the residue was treated with saturated aqueous sodium metabisulphite solution (300ml). The resulting white solid was filtered off, washed well with water (200ml), and dried, to give 3-benzoyloxy-4-methoxybenzoic acid (29.3g), m.p. 180-183°C.

REFERENCE EXAMPLE 10

A solution of 3-benzoyloxy-4-methoxybenzoic acid (29.3g; prepared as described in Reference Example 9) in toluene (300ml) was treated with thionyl chloride (30ml) and heated on the steam bath for 6 hours. It was then cooled, filtered and concentrated, to give 3-benzoyloxy-4-methoxybenzoyl chloride (28.7g), m.p. 120-122°C.

- 54 -

REFERENCE EXAMPLE 11

By proceeding in a manner similar to that described in Example 8, but using 3-benzoyloxy-4-methoxybenzoyl chloride (prepared as described in Reference Example 10) and 4-amino-3,5-dichloropyridine (prepared as described in Reference Example 4) as starting materials, there was prepared N-(3,5-dichloropyrid-4-yl)-3-benzoyloxy-4-methoxybenzamide, m.p. 191-192°C.

REFERENCE EXAMPLE 12

A solution of N-(3,5-dichloropyrid-4-yl)-3-benzoyloxy-4-methoxybenzamide (13.4g; prepared as described in Reference Example 11) in methanol (160ml) and water (60ml) was treated with anhydrous potassium carbonate (18g), and stirred overnight at room temperature. It was then brought to pH7 by treatment with dilute hydrochloric acid (2N), and concentrated. The residue was treated with water (100ml) and filtered, and the resulting solid was dried, to give N-(3,5-dichloropyrid-4-yl)-3-hydroxy-4-methoxybenzamide (8.8g), m.p. 227-228°C.

REFERENCE EXAMPLE 13

By proceeding in a manner similar to that described in Reference Example 2, but using the appropriate quantities of 3-(exo-8,9,10-trinorbornyl-

- 55 -

2-oxy)-4-methoxybenzaldehyde (prepared as described in Reference Example 7) and (R)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzaldehyde and (S)-3-(exo-8,9,10-trinorbornyl-2-oxy)-4-methoxybenzaldehyde [similarly prepared from (R)-endo-8,9,10-trinorborneol and (S)-endo-8,9,10-trinorborneol or as described in the specification of European Patent Publication No. 0428302A2] there were prepared:-

3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoic acid, m.p. 155-156°C;

(R)-3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoic acid, m.p. 155-156°C; and

(S)-3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoic acid, m.p. 155-156°C.

REFERENCE EXAMPLE 14

By proceeding in a manner similar to that described in Reference Example 3, but using the appropriate quantities of the corresponding benzoic acid derivatives, prepared as described hereinbefore in Reference Example 13, there were prepared:-

3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoyl chloride;

(R)-3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoyl chloride; and

(S)-3-(exo)-8,9,10-trinorbornyl-2-oxy-4-methoxybenzoyl chloride; each in the form of oils.

- 56 -

The present invention also includes within its scope pharmaceutical formulations which comprise at least one of the compounds of formula I or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or coating.

In clinical practice compounds of the present invention may be administered parenterally, rectally or orally, but they are preferably administered by inhalation.

Suitable compositions containing compounds of the invention and pharmaceutically acceptable salts thereof may be prepared by conventional means. For example, compounds of the invention and pharmaceutically acceptable salts thereof may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for oral administration include compressed tablets, pills, powders and granules. In such solid compositions, one or more of the active compounds is, or are, admixed with at least one inert diluent such as starch, sucrose or lactose. The compositions may also comprise, as is normal practice, additional substances other than inert

- 57 -

diluents, e.g. lubricating agents, such as magnesium stearate.

Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs containing inert diluents commonly used in the art such as water and liquid paraffin. Besides inert diluents such compositions may comprise adjuvants, such as wetting and suspending agents, and sweetening, flavouring, perfuming and preserving agents. The compositions according to the invention for oral administration also include capsules of absorbable material such as gelatin, containing one or more of the active substances with or without the addition of diluents or excipients.

Compositions according to the invention for parenteral administration include sterile aqueous, aqueous-organic, and organic solutions, suspensions and emulsions. Examples of organic solvents or suspending media are propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate. The compositions may also contain adjuvants such as stabilising, preserving, wetting, emulsifying and dispersing agents. They may be sterilised, for example, by filtration through a bacteria-retaining filter, by incorporation in the

- 58 -

compositions of sterilising agents, by irradiation or by heating. They may also be manufactured in the form of sterile solid compositions, which can be dissolved in sterile water or some other sterile injectable medium immediately before use.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of formula I.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation.

- 59 -

The following Composition Examples illustrate pharmaceutical compositions according to the present invention.

COMPOSITION EXAMPLE 1

N-(2,6-difluorophenyl)-3-cyclopentyloxy-4-methoxybenzamide (1.0g) (mean particle size 3.5 microns) and lactose (mean particle size 72 microns) were blended together for 30 minutes in a mechanical shaker/mixer. The resulting blend was filled, to a fill weight of 25mg, into No.3 hard gelatine capsules, to give a product suitable for use, for example, with a dry powder inhaler.


COMPOSITION EXAMPLE 2

N-(3,5-dichloropyrid-4-yl)-3-cyclopentyloxy-4-methoxybenzamide (1.0g) (mean particle size 3.5 microns) and lactose (mean particle size 72 microns) were blended together for 30 minutes in a mechanical shaker/mixer. The resulting blend was filled, to a fill weight of 25mg, into No.3 hard gelatine capsules, to give a product suitable for use, for example, with a dry powder inhaler.

-60-

CLAIMS

1. A benzamide derivative of the general formula (I):



wherein R¹ represents a straight- or branched-chain alkyl group containing up to 4 carbon atoms, R² represents a straight- or branched-chain alkyl group containing from 2 to 15 carbon atoms or a mono-, bi- or tricycloalkyl group containing up to 10 carbon atoms, R³ represents an optionally substituted phenyl, naphthyl or heterocyclyl group, and Z represents an oxygen or sulphur atom, and when said heterocyclyl groups contain one or more nitrogen ring atoms, N-oxides thereof, and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein the heterocyclyl group is a 5-, 6- or 7-membered heterocyclyl group containing one or more hetero atoms selected from oxygen, sulphur and nitrogen atoms, and the optional substituents on phenyl, naphthyl or heterocyclyl being one or more substituents selected from halogen atoms, alkyl groups which may carry one or more halogen atoms, and from aryl, arylalkyl, alkoxy, aryloxy, alkylthio, arylthio, alkoxycarbonyl, aryloxycarbonyl, alkanoyl, aroyl,

-61-

alkylsulphonyl, arylsulphonyl, alkylsulphinyl, arylsulphinyl, hydroxy, hydroxyalkyl, formyl, alkanoylamino, aroylamino, cyano and nitro groups, and from amino, carbamoyl and sulphamoyl groups which themselves may each carry one or two alkyl substituents, wherein all aryl groups and moieties, unless otherwise indicated, are selected from phenyl and naphthyl groups optionally substituted by one or more substituents selected from halogen atoms and alkyl and alkoxy groups, and wherein all alkyl groups and moieties, unless otherwise indicated, are straight- or branched-chain and contain up to 4 carbon atoms.

3. A compound according to claim 1 or 2 wherein R^2 represents a straight- or branched-chain alkyl group containing from 2 to 12 carbon atoms.

4. A compound according to claim 1 wherein at least one of the symbols has a value selected from the following:-

- (i) R^1 represents a methyl group;
- (ii) R^2 represents a propyl, butyl, nonyl, dodecyl, cyclohexyl, 8,9,10-trinorbornyl or cyclopentyl group; and/or
- (iii) R^3 represents an optionally substituted pyrazinyl, pyrimidinyl, isoxazolyl, or pyridyl group, or an N-oxide thereof, or an optionally substituted phenyl group;

the other symbols being as hereinbefore defined.

-62-

5. A compound according to claim 4 wherein R^2 represents cyclopentyl and R^3 represents optionally substituted pyridyl.


6. A compound according to any one of preceding claims wherein R^3 represents a phenyl group which is substituted in the 2-position or in the 2- and 6-positions.

7. A compound according to any one of claims 1 to 5 wherein R^3 represents a heterocyclyl group substituted on one or both of the positions next to the point of attachment to the rest of the molecule.

8. A compound according to claim 1 which is hereinbefore identified as any one of A to BX or a pharmaceutically acceptable salt thereof.

9. A process for the preparation of a compound according to claim 1 which comprises

- (a) the reaction of a compound of the general formula (II):



(II)


wherein R^1 and R^2 are as defined in claim 1 and X^1 represents a halogen atom with a compound of the general formula (III):



-63-

wherein R^3 is as defined in claim 1; or

(b) the reaction of a compound of the general formula (IV):



wherein R^1 , R^3 and Z are as defined in claim 1 with a compound of the general formula (V):



wherein R^2 is as defined in claim 1 and X^2 represents a halogen atom;

optionally followed by the conversion of a compound of general formula (I) thus obtained into another compound of general formula (I);

and optionally converting the compound of general formula (I) thus obtained into a salt thereof.

10. A pharmaceutical composition which comprises a benzamide derivative of general formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable carrier or coating.

11. A method for the treatment of a human or animal patient suffering from, or subject to, a condition which can

-64-

be ameliorated by the administration of an inhibitor of cyclic AMP phosphodiesterase, which method comprises the administration of an effective amount of a benzamide derivative as defined in claim 1 or a pharmaceutically acceptable salt thereof.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 92/00153

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C07C235/36; C07C321/30;	A61K31/165; C07C255/60; C07C311/39; C07C327/48; A61K31/18 C07D213/75
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07C ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	JOURNAL OF MEDICINAL CHEMISTRY. vol. 16, no. 4, April 1973, WASHINGTON US pages 332 - 336; I.W. MATHISON ET AL.: 'SYNTHESIS AND HYPOTENSIVE PROPERTIES OF TETRAHYDROISO QUINOLINES' see the whole document ---	1-11
A	CHEMICAL ABSTRACTS, vol. 108, no. 15, 11 April 1988, Columbus, Ohio, US; abstract no. 131583P, 'PREPARATION OF N-PYRIDYL-4-(BENZYLOXY)BENZAMIDES AS CARDIOTONICS' page 733 ; see abstract & JP,A,62 158 253 (KIRIN BREWERY CO., LTD) 14 July 1987 --- -/--	1-11
<p>¹⁰ Special categories of cited documents : ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
08 MAY 1992	27. 05. 92	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	SANCHEZ Y GARCIA J.	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category ^a	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	CHEMICAL ABSTRACTS, vol. 99, no. 6, 8 August 1983, Columbus, Ohio, US; abstract no. 43556Z, 'HYPOGLYCEMIC PHARMACEUTICALS CONTAINING BENZAMIDE DERIVATIVES' page 322 ; see abstract & JP,A,5 869 812 (CHUGAI PHARMACEUTICAL CO. LTD.) 26 April 1983 ---	1-11
A	BULLETIN DE LA SOCIETE CHIMIQUE DE FRANCE. 1965, PARIS FR pages 848 - 857; P.GRAMMATICAKIS: 'CONTRIBUTION A L'ETUDE DE L'ABSORPTION DANS L'ULTRAVIOLET MOYEN ET LE VISIBLE DES N-AROYL-ARYLAMINES. IV.' see page 849 ---	1-9

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9200153
SA 55912

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 08/05/92

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
JP-A-62158253	14-07-87	None	
JP-A-5869812		None	

(19) 日本国特許庁 (J P)

(12) 公開特許公報 (A)

(11) 特許出願公開番号

特開平4-253945

(43) 公開日 平成4年(1992)9月9日

(51) Int.Cl. ⁵	識別記号	庁内整理番号	F I	技術表示箇所
C 0 7 C 251/62		8318-4H		
A 6 1 K 31/15	A B E	8413-4C		
	A C F	8413-4C		
31/47		7252-4C		
C 0 7 C 271/60		6917-4H		

審査請求 未請求 請求項の数14(全 16 頁) 最終頁に続く


(21) 出願番号	特願平3-195183	(71) 出願人	591011502 アメリカン・ホーム・プロダクツ・コーポ レイション AMERICAN HOME PRODU CTS CORPORATION アメリカ合衆国10017ニューヨーク州ニュ ーヨーク、サード・アベニュー685番
(22) 出願日	平成3年(1991)8月5日	(72) 発明者	ルイス・ジョン・ランバード アメリカ合衆国08502ニュージャージー州 ベル・ミード、サウス・ウツズ・ロード 412番
(31) 優先権主張番号	5 6 4 2 6 3	(74) 代理人	弁理士 青山 葆 (外1名)
(32) 優先日	1990年8月8日		
(33) 優先権主張国	米国 (U S)		

(54) 【発明の名称】 気管支拡張剤および抗-炎症剤としてのオキシム-カルバメートおよびオキシム-カルボネート

(57) 【要約】 (修正有)

【目的】 急性および慢性気管支喘息の治療および関連
病理学に有用な新規化合物を提供する。

【構成】 I 式



例えば1-〔3-(シクロペンチルオキシ)-4-メトキシ
シフエニル〕エタノン(E)-0-(アミノカルボニ
ル)オキシムで示される化合物。

(19) 日本国特許庁 (J P)

(12) 公表特許公報 (A)

(11) 特許出願公表番号

特表平6-504782

第3部門第2区分

(43) 公表日 平成6年(1994)6月2日

(51) Int. Cl.³

C 0 7 C 235/38

327/48

識別記号

庁内整理番号

F 1

7106-4H

7106-4H

審査請求 未請求 予備審査請求 有 (全 19 頁)

(21) 出願番号 特願平4-503280
 (36) (22) 出願日 平成4年(1992)1月28日
 (85) 翻訳文提出日 平成5年(1993)7月28日
 (86) 国際出願番号 PCT/GB92/00153
 (87) 国際公開番号 WO92/12961
 (87) 国際公開日 平成4年(1992)8月6日
 (31) 優先権主張番号 9101777.2
 (32) 優先日 1991年1月28日
 (33) 優先権主張国 イギリス (GB)
 (31) 優先権主張番号 9117727.9
 (32) 優先日 1991年8月16日
 (33) 優先権主張国 イギリス (GB)


(71) 出願人 ローナー・ブーラン・ロレ・リミテッド
 イギリス国イースト サセックス ビーエヌ21 3ワイジー・イーストボーン セントレオナズロード・アールビーアールハウス (番地なし)
 (72) 発明者 アシュトン、マイケル・ジョン
 イギリス国エセックス アールエム10 7 エックスエス・デジエンハム・レインハムロードサウス (番地なし)・ローナー・ブーランロレリミテッド内
 (74) 代理人 弁護士 小田島 平吉

最終頁に続く

(54) 【発明の名称】 ベンズアミド

(57) 【要約】

式 (1)



式中、R¹はアルキルであり、R²はアルキルまたはモノー、ビーまたはトリシクロアルキルであり、R³は置換されていてもよいフェニル、ナフチルまたはヘテロサイクルの基であり、そしてZは酸素または硫黄である、のベンズアミド誘導体、および前記ヘテロサイクル基が1または2以上の窒素環原子を含有するとき、それらのN-オキシド、および製剤学的に許容される塩は、有用な薬理学的性質を有する。

(19) 日本国特許庁 (J P)

(12) 公表特許公報 (A)

(11) 特許出願公表番号

特表平7-504442

第3部門第2区分

(43) 公表日 平成7年(1995)5月18日

(51) Int. Cl. ⁴	識別記号	序内整理番号	F 1
C 0 7 C 43/225	C	7419-4H	
A 6 1 K 31/135		9454-4C	
31/165			
31/17			

審査請求 未請求 予備審査請求 未請求(全 37 頁) 最終頁に続く

(21) 出願番号	特願平6-514949
(86) (22) 出願日	平成5年(1993)12月23日
(85) 翻訳文提出日	平成6年(1994)8月23日
(86) 国際出願番号	P C T / G B 9 3 / 0 2 6 2 5
(87) 国際公開番号	W O 9 4 / 1 4 7 4 2
(87) 国際公開日	平成6年(1994)7月7日
(31) 優先権主張番号	9 2 2 6 8 3 1, 7
(32) 優先日	1992年12月23日
(33) 優先権主張国	イギリス (GB)
(31) 優先権主張番号	9 3 1 5 9 6 6, 3
(32) 優先日	1993年8月2日
(33) 優先権主張国	イギリス (GB)


(71) 出願人	セルテック リミテッド
	イギリス, パークシャー エスエル1 4
	イーエヌ, スルー, パス ロード 216
(72) 発明者	ワレロー, グラハム ジョン
	イギリス, ミドルセックス エイチエイ6
	3 キューユー, ノースウッド, ウィーラ
	ンド ロード 4
(72) 発明者	ボイド, イワン キャンベル
	イギリス, パークシャー エスエル1 9
	エイチビー, スルー, ハイグ ドライブ
	2
(74) 代理人	弁理士 太田 恵一

最終頁に続く

(54) 【発明の名称】 ホスホジエステラーゼ阻害剤としての三置換フェニル誘導体

(57) 【要約】

一般的化学式(1)で表される化合物、並びにそれらの塩、溶媒和物、水和物およびN-オキシドが記載される:



(1)

この化学式において、Yはハロゲン原子またはR¹が随意に置換されたアルキル基である-O R¹基であり、Xは-O-, -S-またはR¹が水素原子またはアルキル基である-N (R¹)-であり、R¹は随意に置換されたアルキル、アルケニル、シクロアルキルまたはシクロアルケニル基であり; R²は水素原子またはハロゲン原子またはR¹が水素原子または随意に置換されたアルキル、アルケニル、アルコキシアルキル、またはアルカノイル基、またはフォルミル、カルボキシアミドまたはチオカルボキシアミド基である-O R¹基であり; 同一であっても異なっても良いR³とR⁴はそれぞれ-(CH₂)_n、Ar

基であり、Arは酸素、硫黄または窒素原子から選択された1つ以上のヘテロ原子を随意に含む単環式または二環式アリル基であり、nはゼロまたは整数1、2または3であり; R⁵は水素原子または随意に置換されたアルキル基であり、R⁶は水素原子または随意に置換されたアルキル基である; 本発明による化合物は強力で選択性があり、経口で有効なPDE 1 V阻害剤であり、喘息その他の疾患の予防と治療に有効である。

(19) 日本国特許庁 (J P)

(12) 公表特許公報 (A)

(11) 特許出願公表番号

特表平8-501318

(43) 公表日 平成8年(1996)2月13日

(51) Int.Cl. ⁶	識別記号	庁内整理番号	F I
C 0 7 C 65/26		9450-4H	
A 6 1 K 31/19	A C D	9455-4C	
31/235	A C F	9455-4C	
31/275		9455-4C	
31/35		9454-4C	

審査請求 有 予備審査請求 有 (全 173 頁) 最終頁に続く

(21) 出願番号 特願平6-513129
 (86) (22) 出願日 平成5年(1993)10月29日
 (85) 翻訳文提出日 平成7年(1995)5月31日
 (86) 国際出願番号 PCT/US93/10228
 (87) 国際公開番号 WO94/12461
 (87) 国際公開日 平成6年(1994)6月9日
 (31) 優先権主張番号 07/984, 408
 (32) 優先日 1992年12月2日
 (33) 優先権主張国 米国 (US)
 (81) 指定国 EP(AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, M C, NL, PT, SE), AU, BR, CA, CZ, J P, KR, NO, NZ, PL, RU, US


(71) 出願人 ファイザー・インク.
 アメリカ合衆国ニューヨーク州ニューヨーク市イースト・フォーティセカンド・ストリート235
 (72) 発明者 ダブランティア, アレン ジェイ.
 アメリカ合衆国コネチカット州レッドヤード市バンプキン・ヒル・ロード 450
 (72) 発明者 エグラー, ジェイムズ エフ.
 アメリカ合衆国コネチカット州ストニントン市エルム・ストリート 184
 (74) 代理人 弁理士 小林 浩

最終頁に続く

(54) 【発明の名称】 選択的PDE▲下I▼▲下V▼阻害物質としてのカテコールジエーテル類

(57) 【要約】

本発明は、ホスホジエステラーゼ (PDE) I V型の選択的阻害物質である4-置換カテコールジエーテル化合物に関する。本発明の化合物は、PDE_{IV}の阻害ならびに、エイズ、喘息、関節炎、気管支炎、慢性閉塞性気道疾患、乾せん、アレルギー性鼻炎、皮膚炎およびおおよび他の炎症性疾患の治療に有用である。本発明は、また、この化合物から成る医薬組成物に関する。



(19) 日本国特許庁 (J P)

(12) 公表特許公報 (A)

(11) 特許出願公表番号

特表平9-500376

(43) 公表日 平成9年(1997)1月14日

(51)Int.Cl. ⁶	識別記号	庁内整理番号	F I	
C 0 7 D 473/34	3 6 1	8415-4C	C 0 7 D 473/34	3 6 1
A 6 1 K 31/52	A B E	9454-4C	A 6 1 K 31/52	A B E
C 0 7 D 473/18		8415-4C	C 0 7 D 473/18	
473/20		8415-4C	473/20	
473/24		8415-4C	473/24	
審査請求 未請求 予備審査請求 有 (全 74 頁)				

(21)出願番号	特願平7-502570	(71)出願人	ユーローセルティーク エス. エイ. ルクセンブルグ国 エールルクセンブルグ ブルヴァード ド ラ ベトルーセ 122番地
(86) (22)出願日	平成6年(1994)6月21日	(72)発明者	カヴァラ, デビッド イギリス国 シービー1 2ディーエック ス ケンブリッジ テニソン アベニュー 5番地
(85)翻訳文提出日	平成7年(1995)12月22日	(72)発明者	ホファー, ピーター スイス国 シーエイチ-4410 リースタル ビルマンシュトラーセ 9番地
(86)国際出願番号	P C T / G B 9 4 / 0 1 3 3 4	(74)代理人	弁理士 平木 祐輔 (外2名)
(87)国際公開番号	W O 9 5 / 0 0 5 1 6		
(87)国際公開日	平成7年(1995)1月5日		
(31)優先権主張番号	9 3 1 2 8 5 3 . 6		
(32)優先日	1993年6月22日		
(33)優先権主張国	イギリス (G B)		

最終頁に続く

(54) 【発明の名称】 PDE-IV阻害活性を有する新規化合物

(57) 【要約】

新規なプリン誘導体及びそれらのイソグアニン及びジチオキサンチン前駆体化合物が開示されている。これら化合物は、気管支又は気管の弛緩活性及び/又は抗炎症活性を有する。本発明は、それらの製造方法、それらを含む医薬組成物、及びそれらの医学的使用に関する。一定の好ましい態様では、本発明は、3-置換及び3,8-二置換6-アミノプリン誘導体に関する。

特 許 主 張	
ドイツ連邦共和国 1974 年 3 月 20 日 第 P 2413935.3 号	
国 197 年 月 日 第 号	
国 197 年 月 日 第 号	



特許料
(2,000円)

特 許 願 (特許法第38条ただし書) (B)

昭和 50 年 3 月 20 日 (後記号なし)

特許庁長官 京 藤 英 雄 殿

1. 発 明 の 名 称

新規 4 - (ポリアルコキシ-フェニル) - 2 - ピロリドンの製法

2. 特許請求の範囲に記載された発明の数 3

3. 発 明 者

住 所 ドイツ連邦共和国ベルリン 42・バイエルンリング 27

氏 名 ラルフ・シュミーマー (ほか 5 名)

4. 特 許 出 願 人

住 所 ドイツ連邦共和国ベルリン 65・ミューレルストラッセ
170/172 およびベルクカーメン・ヴァルトストラ
ッセ 14

名 称 シエーリング・アクチエンゲゼルシャフト

代表者 カール・ハインツ・ハフプロフスキー

同 カール・アルフレヒト・クム


国 籍 ドイツ連邦共和国

5. 代 理 人 千 100

住 所 東京都千代田区丸の内 3 丁目 3 番 1 号

新東京ビルディング 電話 (216) 5031-5 番

氏 名 (0017) 弁理士 ローランド・ゾンテルホフ
(ほか 1 名)



① 日本国特許庁

公開特許公報

① 特開昭 50-157360

④ 公開日 昭 50. (1975) 12. 19

② 特願昭 50-34220

② 出願日 昭 50. (1975) 3. 20

審査請求 未請求

(全 16 頁)

庁内整理番号

7242 44
5647 44

⑤ 日本分類

16 E331
30 B4

⑤ Int. Cl?

C07D207/24
A61K 31/40


明 細 書

1. 発 明 の 名 称

新規 4 - (ポリアルコキシ-フェニル) - 2 -
- ピロリドンの製法

2. 特許請求の範囲


(1) 一般式 I:



(I)

〔式中：R₁、及び R₂ は同じものか又は異なるものであり、1 個以上のハロゲン原子、ヒドロキシ基、カルボキシ基、アルコキシ基、アルコキシカルボニル基、カルボキシアミド基又は場合により置換されているアミノ基により置換されている 1 8 個までの C 原子を有する炭化水素基又は 1 ~ 5 個の C 原子を有するアルキル基を表

わすか、又は R₁ と R₂ とが共同で 1 ~ 3 個の C 原子を有するアルキレン基を表わし、R₃ は水素原子又はメトキシ基を表わし、R₄ は水素原子、アルキル基、アリール基又はアシル基を表わし、X は炭素原子又は硫黄原子を表わす〕のラセミ及び光学活性 4 - (ポリアルコキシ-フェニル) - 2 - ピロリドンを製造するに当り、一般式 II:



(II)

〔式中：R₁'、及び R₂' は R₁、及び R₂ か又は水素原子を表わし、R₃ は上記のものを表わし、R は有利に低級アシル基を表わす〕の 4 - (置換フェニル) - 2 - ピロリドン - 3 - カルボン酸アル